← All trials
NCT04358523
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2020
- Primary completion
- May 24, 2020
- Completion date
- May 30, 2020
- First posted
- Apr 24, 2020
- Last posted
- Apr 24, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascletis Pharmaceuticals Co., Ltd.Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.